CDH11 and prostate carcinoma: In contrast, disruption of homotypic CDH11 interactions by an antibody targeting amino acids 343–348 on the CDH11 extracellular EC3 domain reduced the metastatic potential of prostate cancer to bone in a mouse model [25].